<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000677</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 125</org_study_id>
    <secondary_id>C89-258</secondary_id>
    <nct_id>NCT00000677</nct_id>
  </id_info>
  <brief_title>SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy</brief_title>
  <official_title>SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness of SCH 39304 as primary treatment of acute
      cryptococcal meningitis in HIV-infected patients. Safety and effectiveness of maintenance
      therapy following successful treatment of acute disease are also evaluated.

      Cryptococcal meningitis is a significant cause of illness and death in HIV-infected patients.
      Intravenous amphotericin B is effective for acute disease but relapse occurs in the majority
      of patients. Maintenance therapy is recommended but must be balanced against the multiple
      toxicities of the drugs used and the problems associated with the weekly administration of
      intravenous therapy. Treatments that are equally or more effective and less toxic than
      traditional methods are needed, especially oral therapy. SCH 39304 is an orally active
      antifungal drug that in animal studies is active against a wide range of systemic fungal
      infections including infections due to Cryptococcus. Features of SCH 39304 suggest that it
      might be of value in the treatment of cryptococcal meningitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cryptococcal meningitis is a significant cause of illness and death in HIV-infected patients.
      Intravenous amphotericin B is effective for acute disease but relapse occurs in the majority
      of patients. Maintenance therapy is recommended but must be balanced against the multiple
      toxicities of the drugs used and the problems associated with the weekly administration of
      intravenous therapy. Treatments that are equally or more effective and less toxic than
      traditional methods are needed, especially oral therapy. SCH 39304 is an orally active
      antifungal drug that in animal studies is active against a wide range of systemic fungal
      infections including infections due to Cryptococcus. Features of SCH 39304 suggest that it
      might be of value in the treatment of cryptococcal meningitis.

      HIV-infected patients with a diagnosis of acute cryptococcal meningitis, previously untreated
      or relapsed following a successfully treated acute episode, are enrolled in the study. SCH
      39304 is administered orally once daily for 3 days followed by a lower dose once daily for 12
      weeks. Patients who respond to primary therapy are randomized to receive SCH 39304
      maintenance therapy at a higher dose once weekly or at the lower dose once daily for up to 12
      months under this protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Meningitis, Cryptococcal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 39304</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Currently approved antiviral therapy.

          -  Maintenance therapy for cytomegalovirus retinitis or toxoplasmosis.

          -  Rifampin.

          -  Isoniazid.

          -  Dilantin or barbiturates if investigator agrees to rigorously monitor anticonvulsant
             drug levels.

          -  Coumarin-type anticoagulants if investigator agrees to rigorously monitor prothrombin
             time.

          -  Prophylactic treatment for Pneumocystis carinii pneumonia (PCP).

        Concurrent Treatment:

        Allowed:

          -  Local radiotherapy for mucocutaneous Kaposi's sarcoma.

        Prior Medication:

        Allowed:

          -  Amphotericin B, up to 1 mg/kg, during the previous 7 days.

        Patients must be HIV positive by 2 methodologies and have either primary cryptococcal
        meningitis with no prior anti-cryptococcal therapy or relapsed disease after prior therapy.

          -  Prior therapy for cryptococcal meningitis is limited to approved drugs.

          -  Written informed consent either from patient or patient's parent or legal guardian is
             required.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  History of hypersensitivity to imidazole or azole compounds.

          -  Central nervous system disease.

          -  Acute opportunistic infection.

          -  Underlying conditions that in the opinion of the investigator could preclude
             assessment of response.

        Concurrent Medication:

        Excluded:

          -  Systemic antifungal drugs other than study drug.

          -  Any investigational drug other than treatment IND drugs.

          -  Oral hypoglycemic agents.

          -  Oral contraceptives.

          -  Cytotoxic chemotherapy.

        Patients with the following are excluded:

          -  Unable to take oral medications.

          -  Concurrent central nervous system disease which in opinion of investigator would
             interfere with assessment of response.

          -  Concurrent acute opportunistic infection requiring therapy (patients who develop an
             acute opportunistic infection after initiation of study medication may remain on study
             medication).

        Prior Medication:

        Excluded within 7 days of study entry:

          -  Amphotericin B, &gt; 1 mg/kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WG Powderly</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Veterans Administration Med Ctr</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Robert Larsen</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Regional Hosp / St Louis Regional Med Ctr</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Veterans Administration / Mount Sinai Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Med Ctr</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holmes Hosp / Univ of Cincinnati Med Ctr</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp of Cleveland / Case Western Reserve Univ</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ Med Ctr</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buckley Braffman Stern Med Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Health Science Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Veterans Administration Hosp</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee BL, Padula AM, TÃ¤uber MG, Chambers HF, Sande MA. Oral SCH 39304 as primary, salvage, and maintenance therapy for cryptococcal meningitis in AIDS. J Acquir Immune Defic Syndr. 1992;5(6):600-4.</citation>
    <PMID>1588494</PMID>
  </reference>
  <verification_date>December 1994</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Sch 39304</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Cryptococcosis</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sch 39304</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

